Neurophet EV/FCF

Mitä Neurophet tekee? Neurophet Inc generates revenue through the development and sale of brain imaging analysis software, including 'Neurophet SCALE PET' for positron emission tomography (PET) image quantitative analysis and 'Neurophet AQUA' for neurodegenerative brain disease diagnosis support. The company also offers therapeutic medical devices and medical artificial intelligence (AI) solutions. Its primary customers are healthcare providers and medical institutions seeking advanced diagnostic tools and AI-driven healthcare technologies. The products are sold directly to hospitals, clinics, and research institutions that require specialized brain imaging and diagnostic support. Neurophet Inc targets the health care technology sector, focusing on neurology and medical imaging applications. The company's revenue streams include software licensing, device sales, and AI solution subscriptions. Neurophet Inc's business model centers on providing innovative medical technology solutions for neurological conditions. The firm's key products address specific clinical needs in neurodegenerative disease diagnosis and PET image analysis, with a focus on accuracy and efficiency for medical professionals. The company's offerings are designed to enhance diagnostic capabilities in healthcare settings. Neurophet on yksi Eurpooliin suosituimmista yhtiöistä.